Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Ulcerative Colitis | Research article

IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis

Authors: Hong Yang, Kaichun Wu, Hongjie Zhang, Qin Owyang, Yinglei Miao, Fang Gu, Naizhong Hu, Kaifang Zou, Jianqiu Sheng, Jin Li, Ping Zheng, Yulan Liu, Junxia Li, Xiaodi Wang, Yongdong Wu, Yaozong Yuan, Chunxiao Chen, Yanhua Pang, Meihua Cui, Jiaming Qian

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Cytomegalovirus (CMV) infection can significantly complicate and worsen the condition of acute severe ulcerative colitis (UC) patients. We aimed to explore the predictive risk factors to prevent and identify CMV infection at an early stage in acute UC patients.

Methods

A total of 115 moderate-to-severe active UC patients from 17 hospitals throughout China were enrolled. Active CMV infection was diagnosed by one of the following: CMV pp65 antigens, CMV IgM antibodies or CMV DNA. We identified the independent risk factors by multivariate analyses.

Results

A total of 64 of 115 active UC patients had active CMV infection. Compared to the non-CMV-infected patients, the CMV-infected patients had a tendency to be male and to exhibit abdominal pain; fever; oral ulcers; eosinopenia; low albumin, immunoglobulin (Ig) A, IgM, and IgG levels; increased high-sensitivity C-reactive protein (hsCRP) levels; hyponatremia; pancolonic lesions; initial onset type; severe activity; and glucocorticoid (high-dose) and immunosuppressive agent use (P < 0.05). In further multivariate analyses, the use of high-dose glucocorticoids (OR 13.55, 95% CI 2.49–73.61, P < 0.01) and immunosuppressive agents (OR 11.23, 95% CI 1.05–119.99, P = 0.04) were independent risk factors for CMV infection. A decrease eosinophil and albumin levels were risk factors for CMV infection. With every 0.1*10^9/L decrease in the peripheral blood eosinophil level or 1 g/L decrease in the serum albumin level, the risk for CMV infection in UC patients increased by 5.21-fold (1/0.192) or 1.19-fold (1/0.839), respectively.

Conclusions

High-dose glucocorticoid and immunosuppressive agent treatment significantly increase the risk of CMV infection, and correcting eosinopenia and low albumin levels may help prevent CMV infection in UC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119(9):924–35.CrossRef Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119(9):924–35.CrossRef
2.
go back to reference Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J. 2013;10:43.CrossRef Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J. 2013;10:43.CrossRef
3.
go back to reference Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101(12):2857–65.CrossRef Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101(12):2857–65.CrossRef
4.
go back to reference Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55(4):1059–65.CrossRef Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55(4):1059–65.CrossRef
5.
go back to reference Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005;37(6):418–23.CrossRef Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005;37(6):418–23.CrossRef
6.
go back to reference Kim JW, Boo SJ, Ye BD, et al. Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2014;8(7):693–701.CrossRef Kim JW, Boo SJ, Ye BD, et al. Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2014;8(7):693–701.CrossRef
7.
go back to reference Zagórowicz E, Bugajski M, Wieszczy P, Pietrzak A, Magdziak A, Mróz A. Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of Cytomegalovirus-positive cells in biopsy is a risk factor for colectomy. J Crohns Colitis. 2016;10(10):1205–11.CrossRef Zagórowicz E, Bugajski M, Wieszczy P, Pietrzak A, Magdziak A, Mróz A. Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of Cytomegalovirus-positive cells in biopsy is a risk factor for colectomy. J Crohns Colitis. 2016;10(10):1205–11.CrossRef
8.
go back to reference Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46(10 Suppl):S59–65.PubMed Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46(10 Suppl):S59–65.PubMed
9.
go back to reference Harbord M, Eliakim R, Bettenworth D, et al. Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(12):1512.CrossRef Harbord M, Eliakim R, Bettenworth D, et al. Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(12):1512.CrossRef
10.
go back to reference Department of inflammatory bowel disease CSoG. Consensus on diagnosis and Management of Inflammatory Bowel Disease. Chin J Dig. 2018;2(3):173–90. Department of inflammatory bowel disease CSoG. Consensus on diagnosis and Management of Inflammatory Bowel Disease. Chin J Dig. 2018;2(3):173–90.
11.
go back to reference Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–8.CrossRef Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–8.CrossRef
12.
go back to reference Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–83.CrossRef Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–83.CrossRef
13.
go back to reference Yang H, Zhou W, Lv H, et al. The association between CMV Viremia or endoscopic features and Histopathological characteristics of CMV colitis in patients with underlying ulcerative colitis. Inflamm Bowel Dis. 2017;23(5):814–21.CrossRef Yang H, Zhou W, Lv H, et al. The association between CMV Viremia or endoscopic features and Histopathological characteristics of CMV colitis in patients with underlying ulcerative colitis. Inflamm Bowel Dis. 2017;23(5):814–21.CrossRef
14.
go back to reference Kim YS, Kim YH, Kim JS, et al. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. Gut Liver. 2014;8(6):643–7.CrossRef Kim YS, Kim YH, Kim JS, et al. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. Gut Liver. 2014;8(6):643–7.CrossRef
15.
go back to reference Lee HS, Park SH, Kim SH, et al. Risk factors and clinical outcomes associated with Cytomegalovirus colitis in patients with acute severe ulcerative colitis. Inflamm Bowel Dis. 2016;22(4):912–8.CrossRef Lee HS, Park SH, Kim SH, et al. Risk factors and clinical outcomes associated with Cytomegalovirus colitis in patients with acute severe ulcerative colitis. Inflamm Bowel Dis. 2016;22(4):912–8.CrossRef
16.
go back to reference Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(8):725–33.CrossRef Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(8):725–33.CrossRef
17.
go back to reference Dennis EA, Smythies LE, Grabski R, et al. Cytomegalovirus promotes intestinal macrophage-mediated mucosal inflammation through induction of Smad7. Mucosal Immunol. 2018;11(6):1694–704.CrossRef Dennis EA, Smythies LE, Grabski R, et al. Cytomegalovirus promotes intestinal macrophage-mediated mucosal inflammation through induction of Smad7. Mucosal Immunol. 2018;11(6):1694–704.CrossRef
18.
go back to reference Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10(3):245–50.CrossRef Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10(3):245–50.CrossRef
19.
go back to reference Cusano AJ, Thies HL, Siegal FP, Dreisbach AW, Maesaka JK. Hyponatremia in patients with acquired immune deficiency syndrome. J Acquir Immune Defic Syndr. 1990;3(10):949–53.PubMed Cusano AJ, Thies HL, Siegal FP, Dreisbach AW, Maesaka JK. Hyponatremia in patients with acquired immune deficiency syndrome. J Acquir Immune Defic Syndr. 1990;3(10):949–53.PubMed
20.
go back to reference Sarmiento E, Fernàndez-Yáñez J, Muñoz P, et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol. 2005;5(1):97–101.CrossRef Sarmiento E, Fernàndez-Yáñez J, Muñoz P, et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol. 2005;5(1):97–101.CrossRef
21.
go back to reference Sarmiento E, Rodríguez-Molina J, Muñoz P, et al. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation. Transplant Proc. 2005;37(9):4046–9.CrossRef Sarmiento E, Rodríguez-Molina J, Muñoz P, et al. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation. Transplant Proc. 2005;37(9):4046–9.CrossRef
22.
go back to reference Zhou LFF, Jiang J, et al. Changes of immunity function in cytomegalovirus infection. Immunol J. 2003;19(1):59–64. Zhou LFF, Jiang J, et al. Changes of immunity function in cytomegalovirus infection. Immunol J. 2003;19(1):59–64.
23.
go back to reference Rai T, Wu X, Shen B. Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3(2):115–21.CrossRef Rai T, Wu X, Shen B. Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3(2):115–21.CrossRef
24.
go back to reference Klemola T, Savilahti E, Koskimies S. Transient IgA and IgM deficiencies are frequent in children with ulcerative colitis. Eur J Pediatr. 1988;147(2):184–7.CrossRef Klemola T, Savilahti E, Koskimies S. Transient IgA and IgM deficiencies are frequent in children with ulcerative colitis. Eur J Pediatr. 1988;147(2):184–7.CrossRef
25.
go back to reference Domènech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14(10):1373–9.CrossRef Domènech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14(10):1373–9.CrossRef
26.
go back to reference Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28(3):365–73.CrossRef Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28(3):365–73.CrossRef
27.
go back to reference Shukla T, Singh S, Tandon P, McCurdy JD. Corticosteroids and Thiopurines, but not tumor necrosis factor antagonists, are associated with Cytomegalovirus reactivation in inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2017;51(5):394–401.CrossRef Shukla T, Singh S, Tandon P, McCurdy JD. Corticosteroids and Thiopurines, but not tumor necrosis factor antagonists, are associated with Cytomegalovirus reactivation in inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2017;51(5):394–401.CrossRef
28.
go back to reference Pillet S, Jarlot C, Courault M, et al. Infliximab does not worsen outcomes during flare-ups associated with Cytomegalovirus infection in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21(7):1580–6.CrossRef Pillet S, Jarlot C, Courault M, et al. Infliximab does not worsen outcomes during flare-ups associated with Cytomegalovirus infection in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21(7):1580–6.CrossRef
29.
go back to reference Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Curr Opin Gastroenterol. 2013;29(1):7–14.CrossRef Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Curr Opin Gastroenterol. 2013;29(1):7–14.CrossRef
30.
go back to reference Bass DA. Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation. J Clin Invest. 1975;56(4):870–9.CrossRef Bass DA. Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation. J Clin Invest. 1975;56(4):870–9.CrossRef
31.
go back to reference Shaaban H, Daniel S, Sison R, Slim J, Perez G. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care. 2010;25(4):570–5.CrossRef Shaaban H, Daniel S, Sison R, Slim J, Perez G. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care. 2010;25(4):570–5.CrossRef
32.
go back to reference Abidi K, Khoudri I, Belayachi J, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care. 2008;12(2):R59.CrossRef Abidi K, Khoudri I, Belayachi J, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care. 2008;12(2):R59.CrossRef
33.
go back to reference Levin A, Yaari S, Stoff R, Caplan O, Wolf DG, Israeli E. Diagnosis of Cytomegalovirus infection during exacerbation of ulcerative colitis. Digestion. 2017;96(3):142–8.CrossRef Levin A, Yaari S, Stoff R, Caplan O, Wolf DG, Israeli E. Diagnosis of Cytomegalovirus infection during exacerbation of ulcerative colitis. Digestion. 2017;96(3):142–8.CrossRef
34.
go back to reference Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and Management of Ulcerative Colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–84.CrossRef Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and Management of Ulcerative Colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–84.CrossRef
Metadata
Title
IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis
Authors
Hong Yang
Kaichun Wu
Hongjie Zhang
Qin Owyang
Yinglei Miao
Fang Gu
Naizhong Hu
Kaifang Zou
Jianqiu Sheng
Jin Li
Ping Zheng
Yulan Liu
Junxia Li
Xiaodi Wang
Yongdong Wu
Yaozong Yuan
Chunxiao Chen
Yanhua Pang
Meihua Cui
Jiaming Qian
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01434-5

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.